AGMB· Health Care› Biotechnology

AgomAb Therapeutics NV

AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases in the United States. More about the company

$9.26

+1.65% today

$456M · Small cap

Market Neutral — Building

Pro read

Pro

Our read

Not enough history to read yet

Setup score

—

Momentum

Steady

Edge

—

Is AGMB early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2026-02-06 → 2026-10-22

S? 37w

2026-02-062026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S? 37w current

Total tracked: 37 weeks across 1 stage run.

AGMB among Biotechnology584th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…584	AGMBAgomAb Therapeutics NV	—	—	−14.0%

vs 52W High

—

Stock is basing below old highs. A volume-backed breakout to new highs would be the Stage 2 signal to watch.

Stage Maturity

Week 36

1w13w26w

Week 36, mature

How long this stock has been basing. Longer bases can produce stronger breakouts, but the breakout itself is the signal.

vs 200 DMA

—

Stock is testing its 200 DMA as part of the base. Reclaiming and holding above it is a key Stage 2 prerequisite.

Rel Volume

0.56x

vs 50-day avg

Volume in Stage 1 basing is typically quiet. A surge in volume on an upside breakout is the signal to watch.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-14.0%

-26.0%

-13.5%

YTD

—

Scan Membership

Not in any current scan.

Recent Stage Timeline

2026-10-22S—

Wk 36 · Vol 0.56x

2026-10-21S—

Wk 36 · Vol 0.27x

2026-10-20S—

Wk 36 · Vol 0.23x

2026-10-19S—

Wk 36 · Vol 0.20x

2026-10-16S—

Wk 35 · Vol 0.49x

2026-10-15S—

Wk 35 · Vol 0.62x

2026-10-14S—

Wk 35 · Vol 0.37x

2026-10-13S—

Wk 35 · Vol 0.37x

2026-10-12S—

Wk 35 · Vol 0.39x

2026-10-09S—

Wk 34 · Vol 0.65x

2026-10-08S—

Wk 34 · Vol 1.46x

2026-10-07S—

Wk 34 · Vol 0.69x

Moving averages & range

50 DMA

$11.57

200 DMA

—

52W High

—

52W Low

—

5D Low

$8.23

Resistance levels (recent highs)

20d High

$11.10

60d High

$15.78

120d High

$17.82

250d High

—

Next resistance

+19.9%

to 20d High

Dividend Yield

0.00%

P/B 3.6

AgomAb Therapeutics NV: quick answers

Which sector and industry is AgomAb Therapeutics NV in?

AgomAb Therapeutics NV is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases in the United States. The company's product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFßR1 for the treatment of Fibrostenosing Crohn's disease, which is in Phase 2a clinical trials; and AGMB-447, an inhaled small molecule inhibitor of ALK5 or TGFßR1 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1 clinical trials. It also develops AGMB-101, a HGF-mimetic monoclonal antibody that acts through agonism or stimulation of the MET receptor and has demonstrated antifibrotic and regenerative activity in preclinical models. The company was incorporated in 2017 and is headquartered in Antwerp, Belgium.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.